Last $3.73 USD
Change Today +0.14 / 3.90%
Volume 1.1M
SQNM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (SQNM) Snapshot

Open
$3.59
Previous Close
$3.59
Day High
$3.80
Day Low
$3.59
52 Week High
12/3/14 - $4.19
52 Week Low
02/7/14 - $2.02
Market Cap
437.8M
Average Volume 10 Days
1.3M
EPS TTM
$-0.41
Shares Outstanding
117.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEQUENOM INC (SQNM)

sequenom inc (SQNM) Related Businessweek News

View More BusinessWeek News

sequenom inc (SQNM) Details

Sequenom, Inc., a life sciences company, provides genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets in the United States and internationally. It operates through two segments, Sequenom Center for Molecular Medicine and Sequenom Bioscience. The Sequenom Center for Molecular Medicine segment provides molecular based, laboratory developed tests (LDTs) with a focus principally on prenatal diseases and conditions, and ophthalmological diseases and conditions. Its LDTs include MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene RHD LDT, a NIPT to determine the presence or absence of fetal Rhesus D factor; and RetnaGene AMD LDT, a genetic test to predict the risk of a patient with dry or early stage age-related macular degeneration. The Sequenom Bioscience segment provides technology and research use only tools, such as the MassARRAY System platform, chip and reagent consumables, software, and biomarker assay panels for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. Its MassARRAY systems are used in a range of DNA/RNA analysis applications, including SNP, genotyping, detection of mutations, analysis of copy number variants, and other structural genome variations, as well as in quantitative gene expression analysis, quantitative DNA methylation analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. This segment also provides contract research services to clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies, academic institutions, and government agencies. The company was founded in 1994 and is headquartered in San Diego, California.

570 Employees
Last Reported Date: 02/27/14
Founded in 1994

sequenom inc (SQNM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $400.0K
Chief Scientific and Strategy Officer
Total Annual Compensation: $375.0K
Consultant
Total Annual Compensation: $354.3K
Compensation as of Fiscal Year 2013.

sequenom inc (SQNM) Key Developments

Illumina, Inc. and Sequenom, Inc. Agree to Settle All Pending Infringement Claims and Other Disputes Between Sequenom and Verinata Health, Inc

Illumina Inc. and Sequenom Inc. announced they have agreed to settle all pending infringement claims and other disputes between Sequenom and Verinata Health Inc. The parties will pool their owned and in-licensed intellectual property directed to noninvasive prenatal testing (NIPT), including patents that will remain the subject of ongoing interference proceedings. Under the agreement, Illumina will have exclusive worldwide rights to utilize the pooled intellectual property to develop and sell in-vitro diagnostic kits for NIPT and to license third-party laboratories wishing to develop and sell their own laboratory-developed NIPT tests under the collection of pooled patents. In addition, Sequenom and Illumina will each have rights to utilize all pooled patents to develop and sell their own respective laboratory-developed NIPT tests. The parties will share the revenue from the patent pool and Illumina will pay Sequenom a royalty on sales of in-vitro diagnostic kits for NIPT. Illumina will make a $50 million upfront payment to Sequenom as part of the overall agreement, as well as certain ongoing commitments for payments to Sequenom from the patent pool structure through 2020.

Sequenom Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 08:30 AM

Sequenom Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 08:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: William J. Welch, Chief Executive Officer, President and Director.

Sequenom Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Gross Margin Guidance for the Year 2014

Sequenom Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, diagnostic services revenue, net was $37,937,000 against $33,268,000 a year ago. Revenues are recorded primarily on a cash basis. In the third quarter, Sequenom Laboratories continued using accrual accounting for several third-party payors and added additional payors on accrual accounting. Loss from operations was $6,041,000 against $27,155,000 a year ago. Loss from continuing operations before income taxes was $8,185,000 against $29,264,000 a year ago. Loss from continuing operations was $6,078,000 or $0.05 per basic and diluted share against $29,344,000 or $0.25 per basic and diluted share a year ago. Net loss was $6,078,000 or $0.05 per basic and diluted share against $28,148,000 or $0.24 per basic and diluted share a year ago. The company also used cash for capital investments of $0.5 million. For the nine months, diagnostic services revenue, net was $114,780,000 against $86,877,000 a year ago. Loss from operations was $33,688,000 against $83,178,000 a year ago. Loss from continuing operations before income taxes was $40,022,000 against $89,648,000 a year ago. Loss from continuing operations was $31,111,000 or $0.27 per basic and diluted share against $89,845,000 or $0.78 per basic and diluted share a year ago. Net loss was $17,299,000 or $0.15 per basic and diluted share against $88,531,000 or $0.77 per basic and diluted share a year ago. The company expects gross margin to improve in the future as it continue its efforts to gain reimbursement and lower the cost of processing its tests.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQNM:US $3.73 USD +0.14

SQNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $19.18 USD +0.42
Enzo Biochem Inc $4.57 USD +0.06
Luminex Corp $18.99 USD +0.39
Pacific Biosciences of California Inc $7.83 USD +0.37
STAAR Surgical Co $9.18 USD +0.07
View Industry Companies
 

Industry Analysis

SQNM

Industry Average

Valuation SQNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit www.sequenom.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.